Regenicin, Inc.
RGIN · OTC
3/31/2023 | 12/31/2022 | 9/30/2022 | 6/30/2022 | |
|---|---|---|---|---|
| Market Cap | $215 | $77 | $491 | $1,688 |
| - Cash | $10,880 | $11,794 | $15 | $2 |
| + Debt | $643 | $643 | $643 | $630 |
| Enterprise Value | -$10,022 | -$11,074 | $1,119 | $2,317 |
| Revenue | $0 | $0 | $0 | $0 |
| % Growth | – | – | – | – |
| Gross Profit | $0 | $0 | $0 | $0 |
| % Margin | – | – | – | – |
| EBITDA | -$327 | -$213 | -$126 | -$153 |
| % Margin | – | – | – | – |
| Net Income | -$336 | -$278 | -$190 | -$164 |
| % Margin | – | – | – | – |
| EPS Diluted | -0.002 | -0.002 | -0.001 | -0.001 |
| % Growth | -21.1% | -58.3% | -9.1% | – |
| Operating Cash Flow | -$328 | -$362 | -$0 | -$10 |
| Capital Expenditures | $0 | $0 | $0 | $0 |
| Free Cash Flow | -$328 | -$362 | -$0 | -$10 |